pharma · Non-small Cell Lung Cancer · Solid Tumors
BioNTech SE
BioNTech SE is a pharma organization headquartered in Mainz, DE. Primary therapeutic focus areas include Non-small Cell Lung Cancer, Solid Tumors, Melanoma (Stage III and IV), Endometrial cancer, Resected (R0 or R1) panc
Company details
- Status
- Public
- HQ
- An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE
- Founded
- 2008
- Employees
- 5,119
- Programs
- 23
- Drugs
- 35
- Patents
- 25
Quick answer
BioNTech SE is a pharma organization headquartered in Mainz, DE. Primary therapeutic focus areas include Non-small Cell Lung Cancer, Solid Tumors, Melanoma (Stage III and IV), Endometrial cancer, Resected (R0 or R1) pancreatic ductal adenocarcinoma. NovaPharmaNews links 23 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (11), phase 1 (7), phase 3 (5).
Company snapshot
Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health
- 23 active pipeline program(s) linked via ClinicalTrials.gov.
- 25 US patent(s) indexed to this assignee profile.
- 23 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for BioNTech SE. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
Recent coverage
BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
BioNTech and Genentech have dosed the first patient in the Phase 1 pancreatic cancer mRNA vaccine trial of autogene cevumeran. Earlier Nature data showed immune responses in 8 of 16 patients and established the study as the first mRNA vaccine trial in pancreatic cancer.
BioNTech and Pfizer's Bispecifics Data: Insights and Implications
BioNTech and Pfizer present promising bispecifics data, while FDA's Pazdur highlights potential opportunities. Discover the implications for the pharma sector.
#ASCO26: Insights on VEGF Bispecifics from BioNTech-BMS and Pfizer-3SBio
This article delves into the new data released at ASCO26 regarding VEGF bispecifics from BioNTech-BMS and Pfizer-3SBio, highlighting implications for the pharmaceutical industry.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- approved
Momentum
Proprietary activity score for BioNTech SE.
1 active signal
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for BioNTech SE.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is BioNTech SE?
-
Is BioNTech SE publicly traded?
-
What drugs does BioNTech SE develop or market?
-
What are the latest developments for BioNTech SE?
-
What therapeutic areas does BioNTech SE focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.